tradingkey.logo

Syndax Pharmaceuticals Inc <SNDX.OQ> expected to post a loss of 23 cents a share - Earnings Preview

ReutersFeb 28, 2025 1:44 PM
  • Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024

  • The New York City-based company is expected to report revenue of $85.912 million, according to the mean estimate from 13 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of 23 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $35.50​, above​ its last closing price of $15.28. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-1.14

-1.11

-0.98

Beat

11.9

Jun. 30 2024

-0.91

-0.91

-0.80

Beat

12.5

Mar. 31 2024

-0.96

-0.98

-0.85

Beat

13.1​

Dec. 31 2023

-0.97

-0.99

-1.00

Missed

-0.6

​​Sep. 30 2023

-0.80

-0.80

-0.73

Beat

8.2

Jun. 30 2023

-0.73

-0.73

-0.64

Beat

12.6​

Mar. 31 2023

-0.60

-0.60

-0.59

Beat

1

Dec. 31 2022

-0.65

-0.65

-0.62

Beat

4.4

This summary was machine generated February 28 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI